Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors

Neoplasia

Volumn 11, Issue 9, 2009, Pages 910-920

  Hillman, Gilda G ^a,b   Singh Gupta, Vinita ^a   Zhang, Hao ^a   Al Bashir, Areen K ^a   Katkuri, Yashwanth ^a   Li, Meng ^a   Yunker, Christopher K ^a   Patel, Amit D ^a   Abrams, Judith ^a   Haacke, E Mark ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 515 Hudson Webber Cancer Research Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG RETENTION; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY TUMOR; LOW DRUG DOSE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; OPTIMAL DRUG DOSE; PAPILLARY CARCINOMA; PERFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MODEL; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; VASCULAR TUMOR;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; CARCINOMA, RENAL CELL; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMMUNOPRECIPITATION; INDOLES; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69249149975     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09618     Document Type: Article

References (44)

1. Jemal A, Siegel R,Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
2. Haas GP and Hillman GG (1996). Update on the role of immunotherapy in the management of kidney cancer. Cancer Control 3, 536-541.
3. Motzer RJ, Bander NH, and Nanus DM (1996). Renal-cell carcinoma. N Engl J Med 335, 865-875.
4. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, and Crawford ED (2001). Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N Engl J Med 345, 1655-1659.
5. Folkman J (2006). Angiogenesis. Annu Rev Med 57, 1-18.
6. Kerbel R and Folkman J (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2, 727-739.
7. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 9, 327-337.
8. Abrams TJ, Lee LB,Murray LJ, Pryer NK, and Cherrington JM(2003). SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2, 471-478.
9. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, and Pryer NK (2003). Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2, 1011-1021.
10. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, et al. (2003). SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20, 757-766.
11. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, et al. (2003). SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101, 3597-3605.
12. Sohal J, Phan VT, Chan PV, Davis EM, Patel B, Kelly LM, Abrams TJ, O'Farrell AM, Gilliland DG, Le Beau MM, et al. (2003). A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101, 3188-3197.
13. Xu L, Tong R, Cochran DM, and Jain RK (2005). Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor β signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 65, 5711-5719.
14. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, et al. (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24, 16-24.
15. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. (2007). Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 356, 115-124.
16. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, et al. (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009 June 1. [Epub ahead of print].
17. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, and Bjarnason G (2007). Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1, S41-S54.
18. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, et al. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011-2019.
19. Telli ML, Witteles RM, Fisher GA, and Srinivas S (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19, 1613-1618.
20. Schmidinger M,ZielinskiCC,VoglUM, Bojic A, Bojic M, Schukro C,RuhsamM, Hejna M, and Schmidinger H (2008). Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26, 5204-5212.
21. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
22. Jain RK (2001). Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7, 987-989.
23. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, et al. (2004). Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563.
24. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, et al. (2000). Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60, 5565-5570.
25. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, and Folkman J (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60, 1878-1886.
26. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, and Kerbel RS (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105, R15-R24.
27. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, and van Oosterom AT (2003). Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88, 1979-1986.
28. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE,Niermann KJ, KelleyMC, Meszoely I, Mayer IA, Herman CR, McManus K, et al. (2007). Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 25, 1-13.
29. Jackson A, O'Connor JP, Parker GJ, and Jayson GC (2007). Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13, 3449-3459.
30. Hahn OM, Yang C,Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, and Stadler WM (2008). Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26, 4572-4578.
31. Hylton N (2006). Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24, 3293-3298.
32. Checkley D, Tessier JJ, Kendrew J, Waterton JC, and Wedge SR (2003). Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89, 1889-1895.
33. Marzola P, Degrassi A, Calderan L, Farace P,Nicolato E, Crescimanno C, Sandri M, Giusti A, Pesenti E, Terron A, et al. (2005). Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 11, 5827-5832.
34. Gaustad JV, Brurberg KG, Simonsen TG, Mollatt CS, and Rofstad EK (2008). Tumor vascularity assessed by magnetic resonance imaging and intravital microscopy imaging. Neoplasia 10, 354-362.
35. Hillman GG, Wang Y, Che M, Raffoul JJ, Yudelev M, Kucuk O, and Sarkar FH (2007). Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model. BMC Cancer 7, 4.
36. Haacke EM, Filleti CL, Gattu R, Ciulla C, Al-Bashir A, Suryanarayanan K, Li M, Latif Z, DelProposto Z, Sehgal V, et al. (2007). New algorithm for quantifying vascular changes in dynamic contrast-enhanced MRI independent of absolute T1 values. Magn Reson Med 58, 463-472.
37. Raffoul JJ, Banerjee S, Singh-Gupta V, Knoll ZE, Fite A, Zhang H, Abrams J, Sarkar FH, and Hillman GG (2007). Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res 67, 2141-2149.
38. Holm S (2009). A simple sequentially rejective multiple test procedure. Scand J Statist 6, 65-70.
39. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, and Jain RK (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64, 3731-3736.
40. Lam JS, Leppert JT, Figlin RA, and Belldegrun AS (2005). Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 66, 1-9.
41. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, and Kerbel RS (2007). Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104, 17069-17074.
42. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, et al. (2008). Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26, 1810-1816.
43. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, et al. (2008). Anti-tumor activity and biomarker analysis of sunitinib in patients with bevacizumabrefractory metastatic renal cell carcinoma. J Clin Oncol 26, 3743-3748.
44. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, and Slamon D (2008). A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 61, 515-524.